Myelin Basic Protein (68-82), Guinea Pig Research Applicatio

Myelin Basic Protein (68-82), Guinea Pig: Research Applications, Clinical Value, and Future Directions in Neuroimmunology
Introduction [Related: how to get suramin]
Myelin Basic Protein (MBP) is a critical component of the myelin sheath, a multilamellar structure that insulates axons in the central nervous system (CNS) and facilitates rapid nerve impulse conduction. The peptide fragment MBP (68-82), derived from guinea pig, has been extensively utilized in neuroimmunological research, particularly as an immunodominant epitope in experimental autoimmune encephalomyelitis (EAE) models. EAE is the most widely used animal model for studying multiple sclerosis (MS), a chronic demyelinating disease of the CNS (Miller et al., 2010, Nat Rev Immunol). The MBP (68-82) peptide is a 15-amino acid sequence (Gln-Lys-Ser-Gln-Arg-Ser-Gln-Asp-Glu-Asn-Pro-Val-Val-His-Phe) that mimics a region of the native MBP protein, making it a potent antigen for inducing T-cell-mediated autoimmunity in susceptible rodent strains (Pettinelli & McFarlin, 1981, J Immunol).
Mechanistically, MBP (68-82) acts as a T-cell epitope, binding to major histocompatibility complex (MHC) class II molecules on antigen-presenting cells (APCs) and activating autoreactive CD4+ T cells. This activation initiates a cascade of immune responses, including cytokine production, blood-brain barrier disruption, and demyelination, which recapitulate key pathological features of MS (Goverman, 2009, Nat Rev Immunol). The guinea pig-derived MBP (68-82) peptide is particularly valued for its high immunogenicity and ability to induce robust EAE in Lewis rats and other susceptible strains, providing a reproducible platform for studying neuroinflammation, demyelination, and therapeutic interventions. [Related: Golgi-Tracker Green]
Clinical Value and Applications [Related: Bleomycin Sulfate]
The primary clinical value of MBP (68-82), guinea pig, lies in its application as a research tool for modeling autoimmune demyelinating diseases. EAE induced by MBP (68-82) closely mirrors the immunopathology of MS, including perivascular infiltration of mononuclear cells, demyelination, and neurological deficits (Baxter, 2007, J Neuropathol Exp Neurol). This model has been instrumental in elucidating the cellular and molecular mechanisms underlying MS, including the roles of T-cell subsets, cytokines, chemokines, and the blood-brain barrier.
Key applications of MBP (68-82) include:
1. **Pathogenesis Studies:** MBP (68-82)-induced EAE enables detailed investigation of T-cell activation, epitope spreading, and neuroinflammatory cascades, providing insights into MS pathogenesis (Sospedra & Martin, 2005, Annu Rev Immunol).
2. **Therapeutic Screening:** The model serves as a preclinical platform for evaluating immunomodulatory agents, monoclonal antibodies, and small molecules targeting neuroinflammation and demyelination (Steinman & Zamvil, 2006, Nat Med).
3. **Biomarker Discovery:** MBP (68-82)-EAE facilitates the identification of molecular biomarkers associated with disease onset, progression, and therapeutic response.
4. **Tolerance Induction:** The peptide is used to test strategies for inducing antigen-specific tolerance, such as peptide-based immunotherapies and tolerogenic dendritic cells (Lutterotti et al., 2013, Sci Transl Med).
5. **Mechanistic Studies:** MBP (68-82) enables dissection of the roles of specific immune cell subsets, cytokines, and signaling pathways in CNS autoimmunity.
Key Challenges and Pain Points Addressed
Current MS research faces several challenges, including the heterogeneity of disease presentation, limited access to human CNS tissue, and the complexity of immune-CNS interactions. The MBP (68-82)-induced EAE model addresses several of these pain points:
- **Reproducibility:** MBP (68-82) provides a highly reproducible and well-characterized model for inducing EAE, reducing variability and enabling standardized experimental protocols (Baxter, 2007).
- **Pathological Fidelity:** The model recapitulates key features of MS, including T-cell-mediated demyelination and neuroinflammation, facilitating translational research.
- **Therapeutic Testing:** It allows for rapid and cost-effective screening of candidate drugs and immunotherapies before clinical trials.
- **Mechanistic Insights:** The peptide enables targeted studies of antigen-specific immune responses, which are difficult to achieve in human subjects.
Despite these advantages, it is important to recognize limitations such as species differences, the acute monophasic nature of EAE in some strains, and the need for complementary models to fully capture MS heterogeneity (Constantinescu et al., 2011, Br J Pharmacol).
Literature Review
A substantial body of literature supports the utility of MBP (68-82), guinea pig, in neuroimmunology research:
1. **Pettinelli & McFarlin (1981, J Immunol):** This seminal study demonstrated that the MBP (68-82) peptide is a potent encephalitogenic epitope in Lewis rats, capable of inducing classical EAE with high incidence and reproducibility. The authors characterized the immunogenicity and T-cell responses to this peptide, establishing its value for EAE induction.
2. **Goverman (2009, Nat Rev Immunol):** Goverman reviewed the use of MBP peptides in EAE models, highlighting the mechanistic insights gained into T-cell recognition, antigen processing, and CNS infiltration. The review emphasized the translational relevance of MBP (68-82)-induced EAE for MS research.
3. **Baxter (2007, J Neuropathol Exp Neurol):** Baxter provided a comprehensive overview of EAE models, noting that MBP (68-82) induces robust and reproducible disease in Lewis rats, with pathological features closely resembling human MS. The study discussed the utility of this model for preclinical drug testing.
4. **Sospedra & Martin (2005, Annu Rev Immunol):** This review discussed the immunological basis of MS and the role of MBP epitopes, including MBP (68-82), in driving autoreactive T-cell responses. The authors highlighted the importance of peptide-based models for dissecting disease mechanisms.
5. **Steinman & Zamvil (2006, Nat Med):** The authors reviewed therapeutic strategies targeting T-cell responses in MS, noting that MBP (68-82)-induced EAE is a valuable tool for preclinical evaluation of immunomodulatory agents.
6. **Lutterotti et al. (2013, Sci Transl Med):** This study explored antigen-specific tolerance induction using myelin peptides, including MBP (68-82), in EAE models. The findings supported the feasibility of peptide-based immunotherapies for MS.
7. **Constantinescu et al. (2011, Br J Pharmacol):** The authors discussed the limitations and translational challenges of EAE models, emphasizing the need for careful interpretation of preclinical data and the complementary use of multiple models.
Experimental Data and Results
Experimental induction of EAE using MBP (68-82), guinea pig, typically involves subcutaneous injection of the peptide emulsified in complete Freund’s adjuvant (CFA), often accompanied by pertussis toxin to enhance blood-brain barrier permeability. In Lewis rats, this protocol reliably induces acute monophasic EAE characterized by ascending paralysis, weight loss, and CNS inflammation (Pettinelli & McFarlin, 1981).
Key findings from experimental studies include:
- **Disease Incidence and Severity:** MBP (68-82) induces EAE in nearly 100% of Lewis rats, with onset occurring 10–14 days post-immunization. Clinical scores range from mild paresis to complete paralysis, depending on dose and adjuvant use (Baxter, 2007).
- **Histopathology:** CNS tissues from affected animals show perivascular cuffing, demyelination, and infiltration of CD4+ T cells and macrophages, mirroring MS lesions (Goverman, 2009).
- **Immunological Responses:** Immunized animals exhibit robust proliferation of MBP (68-82)-specific T cells, production of pro-inflammatory cytokines (e.g., IFN-γ, TNF-α), and upregulation of adhesion molecules facilitating CNS entry (Sospedra & Martin, 2005).
- **Therapeutic Modulation:** Administration of immunomodulatory agents (e.g., glatiramer acetate, anti-CD4 antibodies) ameliorates disease severity, validating the model for preclinical drug screening (Steinman & Zamvil, 2006).
- **Tolerance Induction:** Repeated administration of MBP (68-82) via mucosal or intravenous routes can induce antigen-specific tolerance, reducing EAE severity and providing a basis for peptide-based therapies (Lutterotti Additional Resources:
Related Websites: APExBIO Technology LLC is a premier provider of Small Molecule Inhibitors/Activators, Compound Libraries, Peptides, Assay Kits, Fluorescent Labels, Enzymes, Modified Nucleotides, mRNA synthesis and various tools for Molecular Biology. We carry a broad product line in over 50 different research areas such as cancer, immunology, neurosciences, apoptosis and epigenetics etc. Based in USA (Houston, Texas), we have been serving the needs of customers across the world.
https://www.apexbt.com/
Research Article: PMC11541566